Nephron sparing treatment for small renal masses
Research type
Research Study
Full title
A feasibility study of a cohort embedded randomised controlled trial comparing NEphron Sparing Treatment (NEST) for small renal masses.
IRAS ID
238841
Contact name
Maxine Tran
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
ISRCTN Number
ISRCTN18156881
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
Background to the research:
There are 12,500 new cases of kidney cancer every year in the UK and it is predicted that this will rise to 16,000 by 2035. The standard treatment for small kidney cancers, is surgical removal of the cancer (partial nephrectomy). However, this is a complex surgery procedure and 1 in 20 patients develop complications such as leakage of urine into the abdomen, bleeding and bowel injury.
An alternative treatment option is cryoablation, which involves killing cancer cells by freezing. It has less complications, faster recovery and gives equally good cancer control. Currently, cryoablation is mainly offered to elderly patients or patients with significant medical problems. It is not clear if it can also benefit other patients. A clinical trial comparing the two options may answer this question. We want to see if patients are willing to be involved in such a trial by conducting a feasibility study first, which if successful will progress to a full trial.
Aims of the research:
To see whether patients with small renal cancers will take part in a study to compare cancer treatment by cryoablation with partial nephrectomy.
Design and methods used:
We aim to recruit 50 patients in this feasibility study, and assess how many can be recruited per month.
Patient and public involvement:
An online survey with Kidney Cancer UK (KCUK) involving ninety-nine patients demonstrated their support and need for such a study.
Our patient representatives helped draft the study protocol, patient information sheets and consent forms. They will represent patient views on the trial management committee, and will have a central role in the design of the full trial and dissemination of study findings.
Dissemination:
The results will be presented at national and international clinical meetings, and communicated to the kidney cancer community through social media and the KCUK and Royal Free Hospital websites.REC name
East Midlands - Derby Research Ethics Committee
REC reference
19/EM/0004
Date of REC Opinion
1 Feb 2019
REC opinion
Further Information Favourable Opinion